Profile data is unavailable for this security.
About the company
Eyepoint Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The Company has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The Company is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.
- Revenue in USD (TTM)41.40m
- Net income in USD-102.25m
- Incorporated2008
- Employees144.00
- LocationEyePoint Pharmaceuticals Inc480 Pleasant St Ste B300WATERTOWN 02472-2468United StatesUSA
- Phone+1 (617) 926-5000
- Fax+1 (617) 926-5050
- Websitehttps://eyepointpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paratek Pharmaceuticals Inc | 160.27m | -63.57m | 111.67m | 268.00 | -- | -- | -- | 0.6968 | -1.18 | -1.18 | 2.97 | -3.02 | 0.8994 | 1.67 | 2.88 | 598,014.90 | -35.67 | -42.62 | -44.19 | -48.16 | 85.61 | -- | -39.66 | -124.08 | 3.22 | -2.66 | 2.99 | -- | 23.13 | 66.26 | -7.59 | -- | -49.69 | -- |
| Cidara Therapeutics Inc | 64.29m | -29.80m | 112.15m | 73.00 | -- | -- | -- | 1.74 | -0.458 | -0.458 | 0.8619 | -0.0401 | 1.05 | -- | 11.49 | 880,657.60 | -48.49 | -70.43 | -101.14 | -120.17 | -- | -- | -46.35 | -166.50 | -- | -- | -- | -- | 29.69 | -- | 29.83 | -- | -17.35 | -- |
| aTyr Pharma Inc | 10.39m | -45.34m | 112.17m | 65.00 | -- | 0.871 | -- | 10.80 | -1.60 | -1.60 | 0.3655 | 2.42 | 0.0983 | -- | 1.70 | 159,784.60 | -42.91 | -45.75 | -47.28 | -53.23 | -- | -- | -436.58 | -722.51 | -- | -- | 0.0175 | -- | -- | -- | -34.26 | -- | 4.58 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -10.46m | 112.50m | 14.00 | -- | 3,769.22 | -- | -- | -0.1689 | -0.1689 | 0.00 | 0.0003 | 0.00 | -- | -- | 0.00 | -22.48 | -- | -26.47 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.24 | -- | -- | -- |
| Personalis Inc | 65.05m | -113.32m | 113.10m | 395.00 | -- | 0.5182 | -- | 1.74 | -2.48 | -2.48 | 1.42 | 4.67 | 0.1888 | 7.28 | 3.71 | 164,676.00 | -32.88 | -26.39 | -36.27 | -33.83 | 20.52 | 29.81 | -174.20 | -79.72 | 5.77 | -- | 0.0118 | -- | -23.92 | 47.26 | -73.73 | -- | 57.44 | -- |
| Galera Therapeutics Inc | 0.00 | -62.22m | 114.78m | 31.00 | -- | -- | -- | -- | -2.30 | -2.30 | 0.00 | -3.83 | 0.00 | -- | -- | 0.00 | -97.72 | -71.31 | -123.17 | -81.63 | -- | -- | -- | -- | -- | -4.63 | 4.59 | -- | -- | -- | 22.74 | -- | -39.91 | -- |
| Eyenovia Inc | 10.00m | -18.90m | 115.59m | 43.00 | -- | 5.59 | -- | 11.56 | -0.5642 | -0.5642 | 0.3168 | 0.5722 | 0.3546 | -- | 7.44 | 232,558.10 | -67.04 | -82.88 | -153.31 | -124.23 | 100.00 | -- | -189.04 | -475.55 | -- | -29.23 | 0.2623 | -- | 600.00 | -- | 35.36 | -- | 95.35 | -- |
| Eyepoint Pharmaceuticals Inc | 41.40m | -102.25m | 116.63m | 144.00 | -- | 1.20 | -- | 2.82 | -2.74 | -2.74 | 1.11 | 2.83 | 0.1866 | 2.56 | 2.45 | 287,527.80 | -46.09 | -- | -53.05 | -- | 79.89 | -- | -246.97 | -- | 4.92 | -74.33 | 0.2924 | -- | 12.09 | -- | -75.04 | -- | -- | -- |
| VolitionRX Ltd | 306.39k | -30.27m | 116.73m | 104.00 | -- | -- | -- | 380.98 | -0.5478 | -0.5478 | 0.0055 | -0.0445 | 0.0134 | -- | 7.20 | 2,946.06 | -133.66 | -102.95 | -270.09 | -139.00 | -- | -- | -9,986.77 | -26,254.27 | -- | -664.58 | 2.88 | -- | 240.28 | -- | -12.88 | -- | 1.96 | -- |
| Puma Biotechnology Inc | 228.03m | 2.00k | 118.94m | 192.00 | -- | 5.47 | 13.33 | 0.5216 | -0.0043 | -0.0043 | 5.10 | 0.4662 | 1.02 | 9.47 | 7.71 | 1,187,662.00 | 0.0009 | -24.02 | 0.0015 | -39.26 | 75.84 | 81.33 | 0.0009 | -22.63 | 1.67 | 2.20 | 0.8198 | -- | -9.92 | 52.46 | 100.01 | -- | -32.63 | -- |
| Chromadex Corp | 72.05m | -16.54m | 118.99m | 113.00 | -- | 4.14 | -- | 1.65 | -0.2405 | -0.2405 | 1.03 | 0.3845 | 1.29 | 2.07 | 16.94 | 637,610.60 | -29.56 | -54.44 | -43.29 | -80.41 | 59.40 | 58.35 | -22.96 | -46.66 | 1.78 | -- | 0.0013 | -- | 6.82 | 27.72 | 39.03 | -- | -24.39 | -- |
| Bioatla Inc | 0.00 | -106.48m | 119.49m | 66.00 | -- | 0.6618 | -- | -- | -2.74 | -2.74 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -44.35 | -- | -48.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -11.61 | -- | -- | -- |
| Mediwound Ltd | 26.50m | -19.60m | 120.90m | 73.00 | -- | 8.46 | -- | 4.56 | -3.85 | -3.85 | 5.32 | 1.51 | 0.7596 | 8.43 | 4.77 | 362,958.90 | -56.19 | -26.49 | -83.43 | -35.20 | 49.69 | 47.32 | -73.97 | -42.93 | 3.64 | -0.7467 | 0.0719 | -- | 11.50 | 60.39 | -44.63 | -- | -12.39 | -- |
| INmune Bio Inc | 374.00k | -27.30m | 121.14m | 10.00 | -- | 2.02 | -- | 323.89 | -1.52 | -1.52 | 0.0209 | 3.35 | 0.0041 | -- | 0.0536 | 37,400.00 | -30.04 | -38.64 | -32.80 | -40.98 | -- | -- | -7,299.20 | -15,877.95 | -- | -12.89 | 0.1965 | -- | 106.63 | -- | 10.02 | -- | -- | -- |
Data as of Mar 29 2023. Currency figures normalised to EyePoint Pharmaceuticals Inc's reporting currency: US Dollar USD
58.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 31 Dec 2022 | 5.73m | 16.81% |
| RA Capital Management LPas of 31 Dec 2022 | 3.37m | 9.89% |
| Suvretta Capital Management LLCas of 31 Dec 2022 | 3.35m | 9.82% |
| Adage Capital Management LPas of 31 Dec 2022 | 1.95m | 5.72% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 1.50m | 4.40% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 1.36m | 3.99% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2022 | 742.58k | 2.18% |
| Millennium Management LLCas of 31 Dec 2022 | 675.43k | 1.98% |
| Verition Fund Management LLCas of 31 Dec 2022 | 555.53k | 1.63% |
| Citadel Advisors LLCas of 31 Dec 2022 | 540.82k | 1.59% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
